Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Alcobra Ltd.
The purpose of this dose finding study is to compare two doses of MG01CI (1400 mg and 700 mg) to Placebo, in adult subjects with PI-ADHD. A crossover study design will allow evaluation of safety/tolerability and efficacy using validated computerized tests. subjects will be randomly assigned in a 1:1:1 ratio to one of three treatment sequences as follows: 1. week 1:1400 mg, week 2:700 mg, week 3:placebo 2. week 1:700 mg,week 2: placebo,week 3:1400 mg 3. week 1: placebo, week2:1400 mg, week 3 700 mg Overview of Study Visits Screening Period: Visit 1 - Screening/Baseline Visit (up to 7 days prior to dosing) Treatment Period: Visit 2 - Day 0 (Randomization Visit) Visit 3 - Day 7 ± 3 days Visit 4 - Day 14 ± 3 days Visit 5 - Day 21 ± 3 days Follow-up period: Visit 6 - Day 28 ± 3 days Study duration for each subject will be up to 35 days .
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
